| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 70121-2517-05 | 70121-2517 | LANREOTIDE ACETATE | LANREOTIDE ACETATE | 120.0 mg/.5mL | Hormonal Therapy | Somatostatin Analog | Subcutaneous | Sep 23, 2026 | In Use | ||
| 68071-3958-03 | 68071-3958 | PREDNISONE | PREDNISONE | 1.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Sep 16, 2026 | In Use | |
| 83831-0145-25 | 83831-0145 | Etoposide | Avopef | 500.0 mg/25mL | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | Sep 14, 2026 | In Use | |
| 69945-0177-01 | 69945-0177 | LUTETIUM OXODOTREOTIDE LU-177 | BEXLUTRY | 10.0 mCi/mL | Radiopharmaceutical | Somatostatin Analog | SSTR2 | Intravenous | Sep 14, 2026 | In Use | |
| 72205-0324-30 | 72205-0324 | Dasatinib | Dasatinib | 140.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sep 11, 2026 | In Use | |
| 72205-0322-30 | 72205-0322 | Dasatinib | Dasatinib | 80.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sep 11, 2026 | In Use | |
| 72205-0323-30 | 72205-0323 | Dasatinib | Dasatinib | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sep 11, 2026 | In Use | |
| 84386-0010-03 | 84386-0010 | Isotretinoin | Isotretinoin | 30.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Sep 10, 2026 | In Use | |
| 84386-0011-03 | 84386-0011 | Isotretinoin | Isotretinoin | 40.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Sep 10, 2026 | In Use | |
| 84386-0009-03 | 84386-0009 | Isotretinoin | Isotretinoin | 20.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Sep 10, 2026 | In Use | |
| 87628-0101-02 | 87628-0101 | Rolapitant | Varubi | 90.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | Sep 8, 2026 | In Use | |
| 83616-0106-11 | 83616-0106 | Vusolimogene oderparepvec-wtpg | Tudriqev | 1000000.0 [PFU]/mL | Immunotherapy | Oncolytic Viral Therapy | GALV-GP-R, GM-CSF | INTRATUMOR | Sep 4, 2026 | In Use | |
| 17856-0815-05 | 17856-0815 | Prednisolone Sodium Phosphate | Prednisolone Sodium Phosphate | 15.0 mg/5mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Sep 4, 2026 | In Use | |
| 00310-0075-01 | 00310-0075 | Camizestrant | ETCAMAH | 75.0 mg/1 | Hormonal Therapy | Estrogen Receptor Antagonist | ERα | Oral | Sep 4, 2026 | In Use | |
| 21586-0211-02 | 21586-0211 | Ifosfamide for Injection | Ifosfamide | 1.0 g/1 | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Sep 4, 2026 | In Use | |
| 83616-0107-11 | 83616-0107 | Vusolimogene oderparepvec-wtpg | Tudriqev | 10000000.0 [PFU]/mL | Immunotherapy | Oncolytic Viral Therapy | GALV-GP-R, GM-CSF | INTRATUMOR | Sep 4, 2026 | In Use | |
| 00310-0075-95 | 00310-0075 | Camizestrant | ETCAMAH | 75.0 mg/1 | Hormonal Therapy | Estrogen Receptor Antagonist | ERα | Oral | Sep 4, 2026 | In Use | |
| 72205-0177-91 | 72205-0177 | Pomalidomide | Pomalidomide | 2.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 2, 2026 | In Use | |
| 72205-0178-21 | 72205-0178 | Pomalidomide | Pomalidomide | 3.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 2, 2026 | In Use | |
| 72205-0177-21 | 72205-0177 | Pomalidomide | Pomalidomide | 2.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 2, 2026 | In Use | |
| 72205-0179-91 | 72205-0179 | Pomalidomide | Pomalidomide | 4.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 2, 2026 | In Use | |
| 72205-0179-21 | 72205-0179 | Pomalidomide | Pomalidomide | 4.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 2, 2026 | In Use | |
| 72205-0178-91 | 72205-0178 | Pomalidomide | Pomalidomide | 3.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 2, 2026 | In Use | |
| 50633-0230-01 | 50633-0230 | Naxitamab | DANYELZA | 40.0 mg/10mL | Immunotherapy | Monoclonal Antibody | GD2 | Intravenous | Sep 1, 2026 | In Use | |
| 72205-0394-01 | 72205-0394 | CLOFARABINE | CLOFARABINE | 1.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Sep 1, 2026 | In Use |
Found 12611 results — Export these results
Home